IGF-1 LR3 vs MGF for dogs
The short answer
Both are IGF-1 family growth factors and should never be run together — they act on overlapping pathways. The meaningful difference is reach. IGF-1 LR3 has a half-life of twenty to thirty hours and acts systemically, which makes it the compound studied for generalised muscle wasting but also the one that can lower blood glucose enough to cause tremors or collapse. MGF has a half-life of roughly fifteen minutes and acts essentially where it is injected, which limits systemic risk but requires placing the injection near the target muscle. For a localised muscle injury, MGF is the more targeted and lower-risk choice. For generalised sarcopenia, MGF cannot cover the territory. Both are contraindicated in dogs with cancer.
Side by side
| IGF-1 LR3 | MGF | |
|---|---|---|
| Evidence grade | Preliminary / in vitro only | Preliminary / in vitro only |
| Half-life | Approximately 20-30 hours | Approximately 15 minutes |
| Scope of action | Systemic | Local to the injection site |
| Hypoglycaemia risk | Meaningful — glucose monitoring required | Minimal due to short systemic exposure |
| Best studied for | Generalised muscle wasting, sarcopenia | Localised muscle repair after injury |
| Cycling requirement | Mandatory 4 weeks off after 4-6 weeks on | Taper over the final 2 weeks |
| Full profile | IGF-1 LR3 for dogs | MGF for dogs |
Safety at a glance
IGF-1 LR3
IGF-1 LR3 demands more caution than anything else on this site apart from the investigational oncology compounds. Two risks are concrete rather than theoretical: it can lower blood glucose enough to cause tremors or collapse, and because IGF-1 signalling drives cell proliferation it is contraindicated in any dog with known or suspected cancer. The mandatory four-week off-cycle exists to let receptor sensitivity recover. Canine evidence is Level V — mechanistic and extrapolated, not clinical.
Is IGF-1 LR3 safe for dogs? →MGF
MGF is among the least-studied compounds on this site in any species, and there is no canine clinical data at all — the evidence is mechanistic. Its very short half-life means systemic exposure is limited, which is reassuring, but it shares the IGF-1 family contraindication: it should not be used in a dog with known or suspected cancer, and it should not be stacked with IGF-1 LR3.
Is MGF safe for dogs? →Common questions
Which is better for dogs, IGF-1 LR3 or MGF?+
Both are IGF-1 family growth factors and should never be run together — they act on overlapping pathways. The meaningful difference is reach. IGF-1 LR3 has a half-life of twenty to thirty hours and acts systemically, which makes it the compound studied for generalised muscle wasting but also the one that can lower blood glucose enough to cause tremors or collapse. MGF has a half-life of roughly fifteen minutes and acts essentially where it is injected, which limits systemic risk but requires placing the injection near the target muscle. For a localised muscle injury, MGF is the more targeted and lower-risk choice. For generalised sarcopenia, MGF cannot cover the territory. Both are contraindicated in dogs with cancer.
Can IGF-1 LR3 and MGF be used together in dogs?+
No. These two should not be combined — see the contraindications on each compound page for the specific reason.
Which has better evidence in dogs, IGF-1 LR3 or MGF?+
IGF-1 LR3 is graded preliminary evidence with 1 cited studies; MGF is graded preliminary evidence with 1 cited studies. Grades reflect the strength of published literature rather than an opinion about efficacy.
References
- 1.Goldspink G Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology, 2005. PMID 16174871
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.